FDA Grants Orphan Drug Status to Genasense for Three Cancer Indications
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Grants Orphan Drug Status to Genasense for Three Cancer Indications

BERKELEY HEIGHTS, NJ -- September 4, 2001 -- Genta Incorporated announced today that Genasense™, its lead anticancer compound, has been granted orphan drug status for three additional cancer indications by the U.S. Food and Drug Administration (FDA).
The designations apply to the Company's applications for such status that were filed in May, 2001 for treatment of patients with multiple myeloma, acute myelocytic leukemia, and chronic lymphocytic leukemia.

Genasense had previously been granted such status for the treatment of patients with malignant melanoma. Orphan drug status provides for a period of marketing exclusivity, certain tax benefits, and an exemption from certain fees at the time of submission for marketing approval of a new drug application (NDA).

"The Company currently has active clinical trials in all four of the indications that have been granted orphan drug Status by FDA, three of which are randomized studies," said Dr. Loretta M. Itri, Genta's Executive Vice-President for Clinical Research and Chief Medical Officer, who also noted: "We remain pleased with the accrual in all of these studies. Assuming a positive result, we remain on track to file our first NDA for Genasense in one of these indications next year."

SOURCE: Genta Incorporated

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities